Suppr超能文献

肠-肝轴、肝硬化和门静脉高压:先有鸡还是先有蛋。

Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First ST SW, Rochester, MN, USA.

Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.

出版信息

Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.

Abstract

The term gut-liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a "chicken and egg" situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.

摘要

“肠-肝轴”一词用于强调肠道和肝脏之间的紧密解剖和功能关系。肠道具有高度特化的上皮膜,可调节黏膜的物质转运。由于肠道菌群失调、肠道屏障受损和免疫状态改变,细菌产物可通过门静脉到达肝脏,在肝脏中被特定受体识别,激活免疫系统并引发炎症反应。肠道微生物群和细菌易位在慢性肝病(包括酒精性和非酒精性脂肪性肝病、肝硬化及其并发症,如门静脉高压、自发性细菌性腹膜炎和肝性脑病)的发病机制中起着重要作用。肠道微生物群还作为胆汁酸代谢的调节剂发挥关键作用,通过法尼醇 X 受体也可以影响肠道通透性和门静脉高压。另一方面,肝硬化和门静脉高压会影响微生物群并增加易位,导致“先有鸡还是先有蛋”的局面,即易位增加门静脉压力,反之亦然。针对肠道微生物群的多种治疗方法已专门在慢性肝病患者中进行了评估。需要进一步研究肠道微生物群及其可能的血流动力学和代谢作用。本文综述了目前关于肠道微生物群在慢性肝病和门静脉高压发病机制中的作用的相关知识。

相似文献

1
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
2
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
J Hepatol. 2019 Dec;71(6):1126-1140. doi: 10.1016/j.jhep.2019.06.017. Epub 2019 Jul 8.
3
Gut-liver axis signaling in portal hypertension.
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917. doi: 10.3748/wjg.v25.i39.5897.
4
The gut-liver axis in liver disease: Pathophysiological basis for therapy.
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
5
Gut microbiota-related complications in cirrhosis.
World J Gastroenterol. 2014 Nov 14;20(42):15624-31. doi: 10.3748/wjg.v20.i42.15624.
6
Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S28-32. doi: 10.1097/MCG.0000000000000347.
7
Gut microbiota and host metabolism in liver cirrhosis.
World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597.
8
Potential mechanisms linking gut microbiota and portal hypertension.
Liver Int. 2019 Apr;39(4):598-609. doi: 10.1111/liv.13986. Epub 2018 Nov 9.
10
Microbiome and bacterial translocation in cirrhosis.
Gastroenterol Hepatol. 2016 Dec;39(10):687-696. doi: 10.1016/j.gastrohep.2015.10.013. Epub 2016 Jan 13.

引用本文的文献

1
Heat-Inactivated FRT4 Alleviates Diet-Induced Obesity via Gut-Liver Axis Reprogramming.
Foods. 2025 Aug 12;14(16):2799. doi: 10.3390/foods14162799.
2
Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.
Front Microbiol. 2025 Jun 19;16:1597145. doi: 10.3389/fmicb.2025.1597145. eCollection 2025.
3
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
4
Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma.
Front Pharmacol. 2025 May 19;16:1595853. doi: 10.3389/fphar.2025.1595853. eCollection 2025.
6
Machine learning algorithms reveal gut microbiota signatures associated with chronic hepatitis B-related hepatic fibrosis.
World J Gastroenterol. 2025 Apr 28;31(16):105985. doi: 10.3748/wjg.v31.i16.105985.
7
Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease.
Biomedicines. 2025 Mar 23;13(4):779. doi: 10.3390/biomedicines13040779.
8
Recent advances in the role of polysaccharides in liver diseases: a review.
Front Pharmacol. 2025 Mar 27;16:1535717. doi: 10.3389/fphar.2025.1535717. eCollection 2025.
9
Hepatic encephalopathy treatment after transjugular intrahepatic portosystemic shunt: a new perspective on the gut microbiota.
Front Med (Lausanne). 2025 Mar 7;12:1423780. doi: 10.3389/fmed.2025.1423780. eCollection 2025.

本文引用的文献

1
Emerging treatments for primary sclerosing cholangitis.
Expert Rev Gastroenterol Hepatol. 2017 May;11(5):451-459. doi: 10.1080/17474124.2017.1293524. Epub 2017 Feb 22.
2
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
J Hepatol. 2017 Apr;66(4):806-815. doi: 10.1016/j.jhep.2016.11.008. Epub 2016 Nov 25.
3
Interaction of gut microbiota with bile acid metabolism and its influence on disease states.
Appl Microbiol Biotechnol. 2017 Jan;101(1):47-64. doi: 10.1007/s00253-016-8006-6. Epub 2016 Nov 25.
5
Gut Microbiota and the Liver: A Tale of 2 Cities: A Narrative View in 2 Acts.
J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S183-S187. doi: 10.1097/MCG.0000000000000699.
6
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1018-G1036. doi: 10.1152/ajpgi.00245.2016. Epub 2016 Sep 29.
7
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Gastroenterology. 2017 Jan;152(1):134-141. doi: 10.1053/j.gastro.2016.09.007. Epub 2016 Sep 14.
8
Non-alcoholic fatty liver and the gut microbiota.
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
9
Gut microbiome and liver disease.
Transl Res. 2017 Jan;179:49-59. doi: 10.1016/j.trsl.2016.07.005. Epub 2016 Jul 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验